View in EDS

Clinical trial and postmarketing safety experience with MenACWY-TT, a meningococcal group A, C, W, and Y tetanus conjugate vaccine.

Saved in:
Bibliographic Details
Title: Clinical trial and postmarketing safety experience with MenACWY-TT, a meningococcal group A, C, W, and Y tetanus conjugate vaccine.
Authors: Serra L; Pfizer Vaccine Emerging Markets and China Medical and Scientific Affairs, Collegeville, PA, USA., Webber C; Pfizer Vaccine Clinical Research and Development, Hurley, UK., Burman C; Pfizer Vaccine Medical Development and Scientific/Clinical Affairs, Collegeville, PA, USA., Bueti P; Pfizer Worldwide Safety, Safety Surveillance and Risk Management, Collegeville, PA, USA., Gorruso M; Pfizer Worldwide Safety, Safety Surveillance and Risk Management, Collegeville, PA, USA., Mather S; Pfizer Worldwide Safety, Safety Surveillance and Risk Management, Collegeville, PA, USA. Electronic address: Susan.Mather@pfizer.com.
Source: Vaccine [Vaccine] 2022 Nov 22; Vol. 40 (49), pp. 7014-7021. Date of Electronic Publication: 2022 Oct 22.
Publication Type: Journal Article; Review; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 36283896
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Clinical trial and postmarketing safety experience with MenACWY-TT, a meningococcal group A, C, W, and Y tetanus conjugate vaccine.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Serra+L%22">Serra L</searchLink>; Pfizer Vaccine Emerging Markets and China Medical and Scientific Affairs, Collegeville, PA, USA.<br /><searchLink fieldCode="AU" term="%22Webber+C%22">Webber C</searchLink>; Pfizer Vaccine Clinical Research and Development, Hurley, UK.<br /><searchLink fieldCode="AU" term="%22Burman+C%22">Burman C</searchLink>; Pfizer Vaccine Medical Development and Scientific/Clinical Affairs, Collegeville, PA, USA.<br /><searchLink fieldCode="AU" term="%22Bueti+P%22">Bueti P</searchLink>; Pfizer Worldwide Safety, Safety Surveillance and Risk Management, Collegeville, PA, USA.<br /><searchLink fieldCode="AU" term="%22Gorruso+M%22">Gorruso M</searchLink>; Pfizer Worldwide Safety, Safety Surveillance and Risk Management, Collegeville, PA, USA.<br /><searchLink fieldCode="AU" term="%22Mather+S%22">Mather S</searchLink>; Pfizer Worldwide Safety, Safety Surveillance and Risk Management, Collegeville, PA, USA. Electronic address: Susan.Mather@pfizer.com.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228406899%22">Vaccine</searchLink> [Vaccine] 2022 Nov 22; Vol. 40 (49), pp. 7014-7021. <i>Date of Electronic Publication: </i>2022 Oct 22.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Review; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Science%22">Elsevier Science </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>8406899 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1873-2518 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220264410X%22">0264410X </searchLink><i>NLM ISO Abbreviation: </i>Vaccine <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36283896
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.vaccine.2022.09.077
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 7014
    Titles:
      – TitleFull: Clinical trial and postmarketing safety experience with MenACWY-TT, a meningococcal group A, C, W, and Y tetanus conjugate vaccine.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Serra L
      – PersonEntity:
          Name:
            NameFull: Webber C
      – PersonEntity:
          Name:
            NameFull: Burman C
      – PersonEntity:
          Name:
            NameFull: Bueti P
      – PersonEntity:
          Name:
            NameFull: Gorruso M
      – PersonEntity:
          Name:
            NameFull: Mather S
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 22
              M: 11
              Text: 2022 Nov 22
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1873-2518
          Numbering:
            – Type: volume
              Value: 40
            – Type: issue
              Value: 49
          Titles:
            – TitleFull: Vaccine
              Type: main
ResultId 1